( An ISO 9001:2015 Certified International Journal )

An International Peer Reviewed Journal for Pharmaceutical, Medical & Biological Sciences

An Official Publication of Society for Advance Healthcare Research (Reg. No. : 01/01/01/31674/16)

European Journal of Pharmaceutical and Medical Research (EJPMR) has indexed with various reputed international bodies like : Google Scholar , Indian Science Publications , InfoBase Index (In Process) , SOCOLAR, China , Research Bible, Fuchu, Tokyo. JAPAN , International Society for Research activity (ISRA) , Scientific Indexing Services (SIS) , Polish Scholarly Bibliography , Global Impact Factor (GIF) (Under Process) , Universal Impact Factor , International Scientific Indexing (ISI), UAE  , Index Copernicus , CAS (A Division of American Chemical Society) USA (Under Process) , Directory of Open Access Journal (DOAJ, Sweden, in process) , UDLedge Science Citation Index , CiteFactor , Directory Of Research Journal Indexing (DRJI) , Indian citation Index (ICI) , Journal Index (JI, Under Process) , Directory of abstract indexing for Journals (DAIJ) , Open Access Journals (Under Process) , Impact Factor Services For International Journals (IFSIJ) , Cosmos Impact Factor , Jour Informatics (Under Process) , Eurasian Scientific Journal Index (ESJI) , International Innovative Journal Impact Factor (IIJIF) , Science Library Index, Dubai, United Arab Emirates , Pubmed Database [NLM ID: 101669306] (Under Process) , IP Indexing (IP Value 2.40) , Web of Science Group (Under Process) , Directory of Research Journals Indexing , Scholar Article Journal Index (SAJI) , International Scientific Indexing ( ISI ) , Scope Database , Academia , 

 ISSN 2394-3211

Impact Factor: 7.065

 ICV - 79.57



Dr. C. Thomas Kingsley, MD; DTCD and *Dr. T. Grashia, MD


Introduction: India accounts for nearly one fifth of the global burden of tuberculosis. India has more new TB cases annually than any other country in the world. The obstacles to success to include poor patient compliance, drug resistance, insufficient duration, and irregular therapy and last but not the least Drug induced Hepatotoxicity. DIH is the most unwanted side effect of ATT. Unfortunately almost all the chemotherapeutic agents used in tuberculosis cause hepatotoxicity by single or multiple mechanisms. Aims and Objectives: The aim of the study is to analyse the incidence of hepatotoxicity in patients taking anti-tuberculous drug therapy under the RNTCP short course schedule in Madurai district and also to analyse the various risk factors for development of hepatotoxicity. Materials and Methodology: A prospective study was conducted among 166 patients selected from amongst those who were registered in the Revised National Tuberculosis Control Programme (RNTCP) of Madurai medical college from June 2007 to June 2008 among which 156 were followed up for 6 months. Results and Discussion: Patients above 18 years with sputum positive tuberculosis and patients coming from within and nearby areas of Madurai were included in the study. Out of 156 patients who were followed up for 6 months, 88 were males and rest were females. The age group most commonly had disease was 15-39 yrs with mean age of 36.6years. Out of 156 patients who completed treatment 24 patients had increase in serum enzymes. Eight patients had symptomatic hepatitis. Patients in older age group, malnutrition and cavitary pulmonary tuberculosis disease had symptomatic hepatitis. Conclusion: Direct correlation existed between increasing ages, malnutrition, anaemia, advanced disease with sputum positivity and hypoproteinemia. Correction of the modifiable risk factors can lead to decrease in hepatotoxicity. Hepatotoxicity is usually self-limiting and treatment need not be discontinued permanently. Serial monitoring of liver function tests will help in early identification of drug induced hepatotoxicity and prevention of fulminant hepatic failure.

Keywords: Anti tubercular treatment (ATT), drug induced hepatotoxicity (DIH), liver function tests.

[Full Text Article] [Download Certificate]


  All Since 2019
 Citation  3086  2560
 h-index  18  17
 i10-index  64  44



  • New Issue Published

    Its Our pleasure to inform you that, EJPMR 1 April 2024 Issue has been Published, Kindly check it on


    APRIL 2024 issue has been successfully launched on APRIL 2024.

  • EJPMR New Impact Factor

    EJPMR Impact Factor has been Increased to 7.065 for Year 2024.

  • Index Copernicus Value

    EJPMR Received Index Copernicus Value 79.57, due to High Quality Publication in EJPMR at International Level

  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.


  • Article Invited for Publication

    Article are invited for publication in EJPMR Coming Issue

Google Scholar Indian Science Publications InfoBase Index (In Process) SOCOLAR, China Research Bible, Fuchu, Tokyo. JAPAN International Society for Research activity (ISRA) Scientific Indexing Services (SIS) Polish Scholarly Bibliography Global Impact Factor (GIF) (Under Process) Universal Impact Factor International Scientific Indexing (ISI), UAE Index Copernicus CAS (A Division of American Chemical Society) USA (Under Process) Directory of Open Access Journal (DOAJ, Sweden, in process) UDLedge Science Citation Index CiteFactor Directory Of Research Journal Indexing (DRJI) Indian citation Index (ICI) Journal Index (JI, Under Process) Directory of abstract indexing for Journals (DAIJ) Open Access Journals (Under Process) Impact Factor Services For International Journals (IFSIJ) Cosmos Impact Factor Jour Informatics (Under Process) Eurasian Scientific Journal Index (ESJI) International Innovative Journal Impact Factor (IIJIF) Science Library Index, Dubai, United Arab Emirates Pubmed Database [NLM ID: 101669306] (Under Process) IP Indexing (IP Value 2.40) Web of Science Group (Under Process) Directory of Research Journals Indexing Scholar Article Journal Index (SAJI) International Scientific Indexing ( ISI ) Scope Database Academia